Loading...

Ultra-LEAF™ Purified anti-human CD3 Antibody Ultra-LEAF™ Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_LEAF_021508
Human peripheral blood lymphocytes stained with LEAF™ purified OKT3, followed by anti-mouse IgG FITC
  • OKT3_LEAF_021508
    Human peripheral blood lymphocytes stained with LEAF™ purified OKT3, followed by anti-mouse IgG FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317350 100 mg NOK27910
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317326 1 mg NOK1329
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317349 50 mg NOK19421
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317347 5 mg NOK4810
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317348 25 mg NOK11616
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317325 100 µg NOK817
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2025. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Loucif H, et al. 2022. Autophagy. 18:1256. PubMed
  2. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  3. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  4. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  5. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  6. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  7. Zheng X, et al. 2022. Cells. 12: . PubMed
  8. Vidard L, et al. 2023. Immun Inflamm Dis. 11:e749. PubMed
  9. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  10. Yen M, et al. 2022. Cell. 185:1414. PubMed
  11. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  12. Beck C, et al. 2023. Biomedicines. 11:. PubMed
  13. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  14. Anderson W, et al. 2023. Elife. 12:. PubMed
  15. Solier S, et al. 2023. Nature. 617:386. PubMed
  16. Si W, et al. 2023. iScience. 26:106529. PubMed
  17. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  18. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  19. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  20. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  21. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
  22. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
  23. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  24. Hsiue EH, et al. 2021. Science. 371:. PubMed
  25. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  26. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
  27. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  28. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  29. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  30. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
  31. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  32. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  33. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
  34. Fang F, et al. 2022. JCI Insight. 7:. PubMed
  35. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  36. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  37. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
  38. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
  39. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  40. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  41. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  42. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  43. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  44. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  45. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  46. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  47. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  48. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  49. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  50. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  51. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  52. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  53. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  54. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  55. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  56. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  57. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
  58. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  59. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
  60. Sekine T, et al. 2020. Cell. 183:158. PubMed
  61. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  62. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
  64. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  65. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  66. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  67. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  68. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
  69. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
  70. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
  71. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  72. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  73. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  74. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
  75. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
  76. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  77. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  78. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
  79. Loucif H, et al. 2022. Autophagy. 18:1256. PubMed
  80. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  81. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  82. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  83. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  84. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  85. Zheng X, et al. 2022. Cells. 12: . PubMed
  86. Vidard L, et al. 2023. Immun Inflamm Dis. 11:e749. PubMed
  87. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  88. Yen M, et al. 2022. Cell. 185:1414. PubMed
  89. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  90. Beck C, et al. 2023. Biomedicines. 11:. PubMed
  91. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  92. Anderson W, et al. 2023. Elife. 12:. PubMed
  93. Solier S, et al. 2023. Nature. 617:386. PubMed
  94. Si W, et al. 2023. iScience. 26:106529. PubMed
  95. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  96. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  97. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  98. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  99. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
  100. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
  101. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  102. Hsiue EH, et al. 2021. Science. 371:. PubMed
  103. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  104. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
  105. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  106. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  107. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  108. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
  109. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  110. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  111. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
  112. Fang F, et al. 2022. JCI Insight. 7:. PubMed
  113. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  114. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  115. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
  116. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
  117. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  118. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  119. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  120. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  121. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  122. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  123. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  124. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  125. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  126. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  127. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  128. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  129. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  130. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  131. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  132. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  133. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  134. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  135. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
  136. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  137. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
  138. Sekine T, et al. 2020. Cell. 183:158. PubMed
  139. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  140. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
  141. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
  142. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  143. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  144. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  145. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  146. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
  147. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
  148. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
  149. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  150. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  151. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  152. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
  153. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
  154. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  155. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  156. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_2749889 (BioLegend Cat. No. 317350)
AB_11150592 (BioLegend Cat. No. 317326)
AB_2749888 (BioLegend Cat. No. 317349)
AB_2571994 (BioLegend Cat. No. 317347)
AB_2571995 (BioLegend Cat. No. 317348)
AB_11147370 (BioLegend Cat. No. 317325)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 6    Revision Date: 07.16.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_LEAF_021508
Human peripheral blood lymphocytes stained with LEAF™ purified OKT3, followed by anti-mouse IgG FITC
  • OKT3_LEAF_021508
    Human peripheral blood lymphocytes stained with LEAF™ purified OKT3, followed by anti-mouse IgG FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317350 100 mg NOK27910
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317326 1 mg NOK1329
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317349 50 mg NOK19421
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317347 5 mg NOK4810
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317348 25 mg NOK11616
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317325 100 µg NOK817
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2025. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Loucif H, et al. 2022. Autophagy. 18:1256. PubMed
  2. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  3. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  4. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  5. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  6. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  7. Zheng X, et al. 2022. Cells. 12: . PubMed
  8. Vidard L, et al. 2023. Immun Inflamm Dis. 11:e749. PubMed
  9. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  10. Yen M, et al. 2022. Cell. 185:1414. PubMed
  11. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  12. Beck C, et al. 2023. Biomedicines. 11:. PubMed
  13. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  14. Anderson W, et al. 2023. Elife. 12:. PubMed
  15. Solier S, et al. 2023. Nature. 617:386. PubMed
  16. Si W, et al. 2023. iScience. 26:106529. PubMed
  17. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  18. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  19. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  20. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  21. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
  22. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
  23. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  24. Hsiue EH, et al. 2021. Science. 371:. PubMed
  25. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  26. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
  27. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  28. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  29. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  30. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
  31. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  32. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  33. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
  34. Fang F, et al. 2022. JCI Insight. 7:. PubMed
  35. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  36. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  37. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
  38. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
  39. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  40. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  41. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  42. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  43. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  44. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  45. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  46. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  47. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  48. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  49. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  50. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  51. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  52. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  53. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  54. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  55. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  56. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  57. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
  58. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  59. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
  60. Sekine T, et al. 2020. Cell. 183:158. PubMed
  61. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  62. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
  64. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  65. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  66. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  67. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  68. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
  69. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
  70. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
  71. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  72. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  73. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  74. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
  75. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
  76. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  77. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  78. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
  79. Loucif H, et al. 2022. Autophagy. 18:1256. PubMed
  80. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  81. McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed
  82. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  83. Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed
  84. Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed
  85. Zheng X, et al. 2022. Cells. 12: . PubMed
  86. Vidard L, et al. 2023. Immun Inflamm Dis. 11:e749. PubMed
  87. Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed
  88. Yen M, et al. 2022. Cell. 185:1414. PubMed
  89. Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed
  90. Beck C, et al. 2023. Biomedicines. 11:. PubMed
  91. Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed
  92. Anderson W, et al. 2023. Elife. 12:. PubMed
  93. Solier S, et al. 2023. Nature. 617:386. PubMed
  94. Si W, et al. 2023. iScience. 26:106529. PubMed
  95. Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed
  96. Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed
  97. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  98. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  99. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
  100. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
  101. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  102. Hsiue EH, et al. 2021. Science. 371:. PubMed
  103. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  104. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
  105. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  106. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  107. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  108. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
  109. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  110. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  111. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
  112. Fang F, et al. 2022. JCI Insight. 7:. PubMed
  113. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  114. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  115. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
  116. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
  117. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  118. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  119. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  120. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  121. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  122. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  123. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  124. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  125. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  126. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  127. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  128. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  129. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  130. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  131. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  132. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  133. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  134. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  135. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
  136. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  137. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
  138. Sekine T, et al. 2020. Cell. 183:158. PubMed
  139. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  140. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
  141. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
  142. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  143. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  144. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  145. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  146. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
  147. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
  148. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
  149. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  150. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  151. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  152. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
  153. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
  154. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  155. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  156. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_2749889 (BioLegend Cat. No. 317350)
AB_11150592 (BioLegend Cat. No. 317326)
AB_2749888 (BioLegend Cat. No. 317349)
AB_2571994 (BioLegend Cat. No. 317347)
AB_2571995 (BioLegend Cat. No. 317348)
AB_11147370 (BioLegend Cat. No. 317325)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 6    Revision Date: 07.16.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account